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Abstract
Introduction Mammographic density is a strong risk factor for
breast cancer. Our objective was to examine its association with
polymorphisms identifying breast cancer susceptibility loci that
were ascertained in recent genome-wide association studies.
Methods Subjects were 825 women who participated in
previous case–control studies of mammographic density and
genetic factors nested within the Multiethnic Cohort study and
were from three ethnic groups (White, Japanese American,
Native Hawaiian). Eight polymorphisms (rs2981582 in FGFR2,
rs3803662 and rs12443621in TOX3, rs3817198 in LSP1,
rs981782 and rs10941679 near HCN1/MRPS30, rs889312
in  MAP3K1, and rs13387042 at 2q) were examined.
Mammographic density was quantified with a computer-
assisted method as the percent dense area: the area of
radiologically dense fibroglandular tissue relative to the total
breast area that also includes radiologically lucent fatty tissue.
Results The polymorphism rs12443621 in TOX3  was
associated with percent dense area; women with at least one G
allele (previously associated with increased breast cancer risk)
had 3% to 4% higher densities than women with two A alleles.
The polymorphism rs10941679 near HCN1/MRPS30 was also
associated with percent dense area; women who were
homozygous for the G allele (previously associated with
increased breast cancer risk) had 4% to 5% lower densities
than women with at least one A allele. The other polymorphisms
were not associated with percent dense area.
Conclusions The available data suggest that the effects of most
of these polymorphisms on breast cancer are not mediated by
mammographic density. Some effects may have been too small
to be detected. The association with rs12443621 may provide
clues as to how variation in TOX3 influences breast cancer risk.
Introduction
Mammographic density is related to breast cancer; women
within the highest categories of mammographic density are at
four to six times higher risk than women within the lowest cat-
egories [1]. Mammographic density is conceptualized most
often as the percentage of the breast area on a mammogram
onto which radiologically dense fibroglandular tissue is pro-
jected. The components of this percentage, dense area and
breast area, can also be considered, but only dense area and
percent dense area are consistently associated with breast
cancer risk [1,2].
Mammographic density is influenced by genetics [2-4], with
up to 65% of its variation estimated to be due to heritable fac-
tors [3,5]. Because breast cancer also has a genetic compo-
nent [6] and is related to mammographic density, they may
share some genetic determinants. Polymorphisms in genes
affecting sex hormones, insulin-like growth factors and DNA
repair – factors putatively or known to be related to breast can-
cer risk – have been examined in relation to mammographic
density, but few clear and replicated relations have been
observed [2,7].
Genome-wide association studies (GWAS) have identified
breast cancer susceptibility loci in or near genes such as
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FGFR2, TOX3 (formerly known as TNRC9), LSP1, HCN1/
MRPS30, MAP3K1 and at 2q that had not previously been
considered [8-10]. Two recent studies examined some of
these loci but found no overall association with mammo-
graphic density [11,12]. Both studies included predominantly
White women, and one study included only premenopausal
breast cancer cases [12]. Our objective was to examine asso-
ciations between polymorphisms identifying breast cancer
susceptibility loci and mammographic density in a sample of
premenopausal and postmenopausal women with and without
breast cancer from the Multiethnic Cohort (MEC) who were
White, Japanese American, and Native Hawaiian. The poly-
morphisms under study have been previously genotyped in the
MEC, have all been identified in GWAS, and either were the
most strongly associated with breast cancer (rs2981582 in
FGFR2  [8], rs3803662 and rs12443621in TOX3  [8,9],
rs889312 in MAP3K1  [8], rs13387042 at 2q [9]), have
shown some indication of association with mammographic
density in previous studies (rs3817198 in LSP1 [11,12]), or
are close to a region found to be linked to mammographic den-
sity (rs981782 and rs10941679 near HCN1/MRPS30 [4]).
Materials and methods
Study population
Subjects were the subset of women who were included in a
case–control study of mammographic density [13,14] and
who were also included in studies of genetic susceptibility
[8,9,15,16] nested within the MEC [17]. The MEC study is a
prospective investigation of lifestyle factors with respect to
cancer outcomes [17]. The cohort was assembled between
1993 and 1996, and included people between the ages of 45
and 75 years in Hawaii and Los Angeles who returned a ques-
tionnaire including information about ethnicity, weight, men-
strual factors, and hormone replacement therapy (HRT) use.
Menopausal status at baseline was inferred from reported ces-
sation of menstrual periods or initiation of HRT use [18]. Par-
ticipants chose all of their applicable racial/ethnic groups from
a list of the most common, writing in any others; those report-
ing mixed ethnicity were assigned to a single group based on
the priority ranking: African American, Native Hawaiian, Latina,
Japanese American, and White. Women were excluded if they
had been diagnosed previously with breast cancer, endome-
trial cancer, or ovarian cancer [17].
The mammographic density study included MEC participants
from Hawaii, and included 607 cases who were diagnosed
with invasive breast cancer by the end of December 2000 and
667 controls who were frequency matched to cases in ethnic
and 5-year age groups [13]. Participants filled out another
questionnaire requesting updated information so that meno-
pausal status, HRT, and weight at the time of each mammo-
gram could be inferred [14].
To enable case–control studies of genetic susceptibility, a
blood sample was requested during 1995 to 2000 from
breast cancer cases occurring in the MEC and from a random
sample of controls, and subsequently from a substantial por-
tion of the MEC participants [15]. These participants have
been included in the replication steps of two GWAS [8,9,16].
In these GWAS, approximately 300,000 single nucleotide pol-
ymorphisms were genotyped in Caucasian populations, either
selected to have a strong family history of breast cancer or not
so selected, to identify those that were most highly associated
with breast cancer risk under a co-dominant model. The most
highly ranked polymorphisms were then tested in several rep-
lication sample sets, one of which included cases and controls
from the MEC. These studies nested in the MEC included
cases diagnosed by the time of the inception of each study
and a selection of controls. The MEC subjects sampled for the
replication steps of the two GWAS largely overlapped.
The current analysis involved 361 cases and 464 controls who
were part of the mammographic density study, had at least one
polymorphism of interest genotyped for the replication steps
of the GWAS, and were in the major ethnic groups repre-
sented in Hawaii (White, Japanese American, Native Hawai-
ian). The MEC and its genetic substudies were approved by
the Institutional Review Boards at the University of Southern
California and the University of Hawaii. The mammographic
density study was approved at the University of Hawaii. Partic-
ipants provided informed consent for both case–control stud-
ies.
Mammographic density
Mammograms were available for a mean of 2.8 different dates
per woman. Mammograms were performed before diagnosis
for all but five cases. For these cases, a mammogram was
available only at the time of diagnosis so the film of the contral-
ateral breast was used. Otherwise, if mammograms from both
breasts were available on a single date, their measures were
averaged.
Films of the craniocaudal view were digitized using a Lumisys
85 scanner (Eastman Kodak, Rochester, NY, USA) that cre-
ates images with pixel size equal to 260 μm and has an optical
density from 0 to 4.1. Mammographic density was determined
using the computer-assisted software, Cumulus, developed at
the University of Toronto, Canada [19]. This software allowed
the reader (GM) to select two thresholds based on pixel
brightness: one to delineate between breast and background,
and another to delineate between nondense and dense areas
in the breast. Percent dense area was estimated from the
dense area divided by the breast area; measurements were
very reliable (intraclass correlation = 0.974; 95% confidence
interval = 0.968 to 0.978) [13].
Genotyping
Blood was obtained from subjects at their homes, processed
within 8 hours, and stored at -80°C. DNA was purified from
white blood cell fractions using the QIAamp 96 DNA Blood KitAvailable online http://breast-cancer-research.com/content/11/1/R10
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(Qiagen, Valencia, CA, USA). The details of the 5'-nuclease
assay (Taqman) [8,9] used for most of the assays and the
Nanongen Centaurus assay used for rs10941679 [16] have
been previously described. For the eight polymorphisms in this
analysis, the average concordance for the blinded duplicates
was 98.8% (1,044/1,056), with a range of 98.1% to 100%.
Statistical analysis
Chi-square test statistics for the hypothesis of Hardy–Wein-
berg equilibrium and the corresponding levels of significance
were calculated by ethnic group. Significant deviation from
what was expected (P < 0.01) only occurred for the rs981782
genotypes among Native Hawaiian subjects (P  = 0.0008),
possibly due to instability arising from small numbers (n = 39).
To investigate the associations between the genotypes and
percent dense area, mixed models were applied to account for
subjects with multiple mammographic readings over time. This
method is nearly equivalent to modeling each woman's aver-
age percent dense area over time except that it uses maximum
likelihood rather than ordinary least squares estimation. The
adjusted mean percent dense area was estimated by geno-
type. Tests for the difference in mean percent dense area and
associated P  values with each allele previously associated
with breast cancer risk (co-dominant, Pc), with any risk allele
(dominant, Pd), or with both risk alleles (recessive, Pr) were
performed. Adjustment was made for age and the square of
age at the time of each mammogram because percent dense
area decreases at a rate that slows over time [14], for ethnicity
because it is associated with genotype and percent dense
area, and for body mass index at the time of each mammogram
because it strengthens the association between percent
dense area and breast cancer risk [20]. Variables for which
adjustment was not made in the models included reproductive
characteristics because they could be on the causal pathway,
family history of breast cancer because it could be a proxy for
genotype, case status because it is theoretically downstream
of mammographic density, and HRT because it was not asso-
ciated with any of the genotypes. Variables for which an inter-
action with the genotypes was investigated, based on
previous literature [7,11,21,22], included case status, ethnic-
ity, and menopausal status with HRT. The absolute amount of
dense area was investigated in similar models. All P values are
two-sided with the level of significance set at P < 0.05. SAS
9.1 (SAS, Cary, NC, USA) was used for the analysis.
Results
For each polymorphism of interest, 634 to 806 subjects were
genotyped; 825 subjects had at least one of the polymor-
phisms genotyped. Characteristics of these 825 subjects are
presented in Table 1. The women had mean ± standard devi-
ation age of 59.5 ± 8.8 years and body mass index of 25.3 ±
5.5 kg/m2. Women were of White (32%), Japanese American
(44%) or Native Hawaiian (24%) ethnicity. At the time of the
first mammogram used in this study, 201 (24%) of the women
were premenopausal; because subjects had multiple mammo-
graphic readings over time, a lower proportion (18%) of mam-
mograms used was taken when the subjects were
premenopausal. The mean percent dense area was 32.7 ±
22.2.
Having any G allele of rs12443621 in TOX3 was associated
with a significantly higher percent dense area than being
homozygous for the A allele (Pd = 0.03) (Figure 1 and Addi-
tional data file 1). This association was modified by menopau-
sal status with HRT (Pinteraction = 0.049) and seemed to be
more pronounced in premenopause. This association was
nonsignificantly stronger in cases than in controls (Pinteraction =
0.054); with dense area, however, the association was signif-
icantly stronger in cases and no association was evident in
controls (Pinteraction  = 0.01). Furthermore, among Whites
homozygotes of the G allele had a higher absolute dense area,
among Native Hawaiians homozygotes of the G allele had a
lower absolute dense area, and no association was observed
among Japanese Americans (Pinteraction = 0.002).
Being homozygous for the G allele of rs10941679 near
HCN1/MRPS30  was associated with a significantly lower
percent dense area than being having any A allele (Pr = 0.02)
(Figure 1 and Additional data file 1). This association was non-
significantly stronger in cases than in controls (Pinteraction =
0.12); with dense area, the association was significantly
stronger in cases (Pinteraction = 0.02).
Percent dense area and dense area were not significantly
associated with any other polymorphism overall and no other
interactions were detected with either case status or ethnicity
(Pinteraction > 0.05). Menopausal status with HRT significantly
modified some associations, suggesting that, in users of com-
bined HRT, being homozygous for the T allele of rs2981582
in FGFR2, being homozygous for the T allele of rs981782 in
HCN1, or being homozygous for the A allele of rs13387042
at 2q35 was associated with decreased dense area (Pinteraction
= 0.02 for all), and each C allele of rs3817198 in LSP1 was
associated with increased percent dense area (Pinteraction =
0.003).
Discussion
The rationale for this investigation was that breast cancer sus-
ceptibility loci may also be related to another strong risk factor,
mammographic density. Two polymorphisms examined were
associated with percent dense area. Women with any G allele
of rs12443621 in TOX3 had 3% to 4% higher percent dense
area than women homozygous for the A allele; the association
was stronger in premenopausal women and breast cancer
cases. Previously, each G allele has been found to be associ-
ated with increased breast cancer risk [8], whereas we found
that a dominant model fit best in explaining variability in mam-
mographic density. In an investigation nested within the
Nurses' Health Study, premenopausal women homozygous forBreast Cancer Research    Vol 11 No 1    Woolcott et al.
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this allele had higher percent dense area and dense area, but
postmenopausal women did not [11]. The polymorphism
rs10941679 near HCN1 and MRPS30 was also associated
with percent dense area; women who were homozygous for
the G allele had 4% to 5% lower densities than women with at
least one A allele. The G allele, however, has been found to be
associated with increased breast cancer risk in a previous
study under a co-dominant model [16]. This polymorphism has
not been examined in previous studies of mammographic den-
sity. Other polymorphisms identifying breast cancer suscepti-
bility loci were not associated with percent dense area or
dense area in the overall samples in the current study or in two
other published studies [11,12]. All studies, however, found
that the C allele of rs3817198 in LSP1 was associated with
higher percent dense area in subgroups of their samples: in
premenopausal women [11], in steroid receptor-positive
cases [12], or in current users of combined HRT in this study.
The polymorphisms examined in the present study were iden-
tified in GWAS of breast cancer [8,9]. The strongest associa-
tions have been found with polymorphisms in FGFR2; each
copy of the T allele of rs2981582 was found to be associated
with a 26% increased breast cancer risk [8]. Because fibrob-
last growth factors and their receptors are thought to provide
a mechanism for epithelial–mesenchymal interactions [23]
and because mammographic density is largely a reflection of
the amount of dense stromal tissue that may provide a permis-
sive environment for neoplastic transformation of the epithelial
cells, we had hypothesized that variation in FGFR2 would be
related to mammographic density. In this study, however, per-
cent dense area was nonsignificantly decreased with the
number of risk alleles.
Polymorphisms in or near TOX3, LSP1, HCN1, MAP3K1 and
at 2q35 are less strongly associated with breast cancer risk
than polymorphisms in FGFR2; the increased risks range from
4% to 20% with each risk allele [8,9,16,24,25]. TOX3 con-
tains a high mobility group box motif that suggests it is a tran-
scription factor [8], but the specific mechanism by which
variation in TOX3 affects breast cancer risk is unknown. Our
results and those of others [11] suggest that mammographic
density could be an intermediate factor, but confirmation from
Table 1
Selected characteristics of the 825 participants
Characteristic Value
Ethnicity
White 262 (31.8%)
Japanese American 361 (43.8%)
Native Hawaiian 202 (24.5%)
Menopausal status, hormone replacement therapy at first mammogram
Premenopausal 201 (24.4%)
Postmenopausal, no hormone replacement therapy 204 (24.7%)
Estrogen only hormone replacement therapy 228 (27.6%)
Estrogen and progestin hormone replacement therapy 192 (23.3%)
Case status
Case 361 (43.8%)
Control 464 (56.2%)
Family history (mother or sister)
Yes 114 (13.8%)
No 711 (86.2%)
Mean age over all mammograms (years) 59.5 ± 8.8
Mean body mass index over all mammograms (kg/m2) 25.3 ± 5.5
Mean percent dense area (%) 32.7 ± 22.2
Mean dense area (cm2) 32.5 ± 25.4
Mean breast area (cm2) 117.1 ± 60.0
Data presented as n (%) or mean ± standard deviation. The set of 825 subjects is the union of the individual sets of 634 to 806 subjects who 
were genotyped for each polymorphism of interest; that is, 825 subjects had at least one polymorphism of interest genotyped.Available online http://breast-cancer-research.com/content/11/1/R10
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other studies is needed. We observed a stronger association
in cases; it could be that cases have other environmental or
genetic factors interacting with TOX3 to increase both mam-
mographic density and breast cancer risk. HCN1 is adjacent
to other genes that may be related to breast cancer risk includ-
ing FGF10 and MRPS30 [16], and is just outside a region
linked to mammographic density [4]. LSP1, lymphocyte-spe-
cific protein 1, may be involved in wound healing [26], which
involves some processes in common with mammary gland
development and involution that could contribute to fibrosis
and, thus, mammographic density [27,28]. Some aspects
about the biology of these genes suggest that polymorphisms
in or near them could affect mammographic density. On the
other hand, some reports suggest that variation in FGFR2,
TOX3, HCN1, and at 2q35 may be more strongly associated
with estrogen receptor-positive cancers [9,16,25], but mam-
mographic density has not been found to be differentially
related to breast cancers by steroid receptor status [29].
A limitation of the current study was that the sample size was
insufficient to detect interactions with case status, ethnicity,
and menopausal status with HRT or to detect small effects.
With the sample size in this study, a linear increase per allele
of 2% to 3% percent dense area could be detected with 80%
power. If an allele increases breast cancer risk between 4%
and 26% [8,9,16] and if the increased risk was entirely medi-
ated by mammographic density, percent dense area would be
expected to be 2% to 13% higher with each allele (an increase
of 1% dense area increases breast cancer risk by approxi-
mately 2% [1]). Differences may not have been detectable if
less than the entire effect was mediated through mammo-
graphic density. Some of the polymorphisms studied seem to
Figure 1
Adjusted mean percent dense area by genotype Adjusted mean percent dense area by genotype. aFrequency of the breast cancer risk allele. bIn order of increasing breast cancer risk observed in 
previous studies [8,9,16]. cAdjusted for age, age squared and body mass index at mammogram and ethnicity. Numeric data are shown in Additional 
data file 1. dPc, co-dominant P value for the per-allele increase in percent dense area; Pd, dominant P value for an increase in percent dense area 
with any risk allele; Pr, recessive P value for an increase in percent dense area with both risk alleles. CI, confidence interval.Breast Cancer Research    Vol 11 No 1    Woolcott et al.
Page 6 of 7
(page number not for citation purposes)
be more strongly related to breast cancer susceptibility in
Whites than Asians [8] and the true effect may have been
smaller in our overall study population, of which nearly one-half
was Japanese American. Furthermore, the causative variants
for breast cancer represented by the polymorphisms identified
in GWAS have not been identified [16] but could be related
more strongly to both breast cancer risk and mammographic
density. Note that no results in the present study would have
been statistically significant if correction had been made for
multiple testing. Whether they were chance findings will need
to be determined by replication in other studies.
Selection bias was unlikely to mask associations. Although our
sample was a subset of the MEC with a slightly different age
and ethnic distribution, we controlled for these factors in the
analysis; other unknown or unmeasured factors that influ-
enced selection into this analysis are probably less likely than
age or ethnicity to be related to either genotypes or mammo-
graphic density. The association between the polymorphisms
and mammographic density is therefore unlikely to have been
modified by these factors.
Conclusions
The rs12443621 polymorphism in TOX3 was associated with
percent dense area under a dominant model. Some biologic
plausibility exists for associations with the other polymor-
phisms examined but possibly the associations were too small
to be detected. The available data, however, suggest that the
effects of most of these polymorphisms on breast cancer are
not mediated by mammographic density. The association of
mammographic density with rs12443621, if confirmed, may
provide clues as to how variation in TOX3 influences breast
cancer risk.
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